NEURACAP
Sector OutlookPublished · 20 pages · Free to read

Health Care Equipment and Supplies Sector Outlook — September 2026

A sector valuation report on Health Care Equipment and Supplies, comparing device platforms, hospital consumables and adjacent models on EV/EBITDA (CY2027E), reviewing precedent transactions, and setting out priorities for owners, management teams and boards.

For information only. Not an appraisal or a fairness opinion.

What moved since: Health Care Equipment and Supplies M&A update, 14–28 September 2026

Key figures

Sector median valuation
10.3x
EV / EBITDA (CY2027E), six of ten rated
Faster-growth cohort multiple
12.2x
EV / EBITDA (CY2027E), above-median growth
Slower-growth cohort multiple
8.1x
EV / EBITDA (CY2027E), below-median growth
Hologic transaction value
$17.9B
Recorded deal value at announcement

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE EQUIPMENT AND SUPPLIES

Health Care Equipment and Supplies: Quality Holds Value

The report shows where public valuations and precedent transactions place value across distinct operating models.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice

1

1 / 20

Executive summary

Health Care Equipment and Supplies spans distinct operating models, and public valuations reflect that split: a 10.3x sector median EV/EBITDA (CY2027E) masks a range from 12.2x for faster-growing names to 8.1x for slower-growing peers. Hospital consumables price higher than device platforms in this set. Precedent transactions, including the $17.9B Hologic deal at 13.6x, show that strategic fit can widen agreed terms. Owners can strengthen their standing by building recurring revenue and protecting earnings quality.

Key findings

  • Sector median forward multiple is 10.3x across six of ten rated companies
  • Faster-growth names price at 12.2x versus 8.1x for slower-growth peers
  • Hospital consumables command higher multiples than device platforms here
  • Strategic conviction supported the $17.9B, 13.6x Hologic transaction

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE EQUIPMENT AND SUPPLIES

    This is the cover page identifying the sector and the report's valuation basis and date.

    We open with Health Care Equipment and Supplies as of September 2026, built on an EV/EBITDA (CY2027E) valuation lens. The pages that follow show where quality holds value across this sector's distinct operating models.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE EQUIPMENT AND SUPPLIES Health Care Equipment and Supplies: Quality Holds Value The report shows where public valuations and precedent transactions place value across distinct operating models. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This page lists the five numbered sections plus the appendix that make up the report.

    We've structured this report so the bottom line comes first: five sections plus an appendix that move from the sector landscape into valuation, precedent deals and strategic implications. A reader who stops after section one still leaves with the whole story, so use what follows to go deeper on what matters most to you.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Value Sits with Durable Growth, Recurring Revenue and Proven Earnings 02 The Landscape One Sector Label Covers Three Distinct Operating Models 03 Valuation & Situations The Valuation Spread Leaves Room for Operating Progress to Matter 04 Precedent Transactions Precedent Transactions Favour Buyers with Conviction 05 Strategic Implications Strengthen the Revenue Engine Before Choosing the Capital Path 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Health Care Equipment and Supplies Span Device Platforms, Hospital Consumables and Adjacent Models

    This page summarizes the report's core finding that the sector splits into device platforms, hospital consumables and adjacent models with different valuation dynamics.

    We find a sector median of 10.3x EV/EBITDA (CY2027E) across six of ten rated companies, and the spread inside that set tells the real story. Faster-growing names price at 12.2x versus 8.1x for slower-growing peers, and hospital consumables carry higher multiples than device platforms. The announced Hologic transaction, valued at $17.9B and 13.6x EV/EBITDA, shows the terms available when buyers underwrite a sizeable platform with strategic conviction. So the question for any owner here is which value engine their business is best positioned to compound.

    Everything on this page

    01 · THE BOTTOM LINE Health Care Equipment and Supplies Span Device Platforms, Hospital Consumables and Adjacent Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (6 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Forward Earnings Support the Primary Valuation Lens The middle of the range is 10.3x across 6 of 10 approved companies with an estimate. With CY2027E earnings already crediting forecast growth, the remaining spread points to differing views of durability. 2 The Premium Sits with Faster Growth Among the six names with an estimate, three above the 4% growth split price at 12.2x, alongside 8.1x for the three below it. The association puts profitable growth at the centre of the value discussion. 3 Business Mix Changes the Value Test Procedural instruments and single-use hospital consumables represent 40% of the set and price at 10.1x, while implantable and therapeutic device platforms represent 40% and price at 7.8x. Installed base, consumables pull-through and reimbursement exposure shape how owners defend revenue quality. 4 Strategic Conviction Can Support Substantial Terms The announced Hologic, Inc. transaction carries a recorded value of $17.9B and 13.6x EV / EBITDA. That benchmark shows the terms available when buyers underwrite a sizeable platform. 10.3x Sector median EV/EBITDA CY2027E consensus · 6 rated of 10 companies 13.7x Premium end EV/EBITDA vs 6.6x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 9 Transactions with disclosed terms 23 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces the section on how the sector's three operating models split by segment.

    One sector label covers three distinct operating models, and each faces a different value test. We use this page to reset before walking through how installed-base economics, hospital consumables and adjacent models compare.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE One Sector Label Covers Three Distinct Operating Models Installed-base economics, hospital consumables and adjacent models face different value tests. 02 of 06 Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Recurring Pull-Through and Capital Exposure Divide the Sector

    This page groups the ten approved companies by business segment and shows the median EV/EBITDA for each group.

    We group all ten approved companies by business segment and compare median EV/EBITDA (CY2027E) across groups. This lets us see where recurring pull-through supports higher valuation and where heavier capital exposure weighs on it. So the segment a company sits in shapes the value test the market applies to it.

    Everything on this page

    02 · MARKET MAP Recurring Pull-Through and Capital Exposure Divide the Sector 10 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 IMPLANTABLE AND THERAPEUTIC DEVICE PLATFORMS 4 cos median 7.8x LivaNova (LIVN) AdaptHealth (AHCO) IRadimed (IRMD) Cerus (CERS) Clinical adoption, reimbursement and therapy concentration shape the durability of these platforms. PROCEDURAL INSTRUMENTS AND SINGLE-USE HOSPITAL CONSUMABLES 4 cos median 10.1x Solventum (SOLV) Baxter (BAX) Stevanato Group (STVN) Nyxoah S.A. (NYXH) Capital placements can seed recurring consumables demand, making attach rate and reorder behaviour central. ADJACENT MODELS 2 cos 12.2x · 1 rated STERIS (STE) Kewaunee (KEQU) These businesses broaden the peer set but require model-specific comparisons.

  6. 06
    02 · LANDSCAPE

    Hospital Consumables Hold the Higher Observed Segment Valuation

    This page shows that hospital consumables hold the higher observed median valuation among the sector's segments.

    Within the approved universe, hospital consumables hold the higher observed segment valuation on an EV/EBITDA (CY2027E) basis. Procedural instruments and single-use consumables, representing 40% of the set, price at 10.1x, while implantable and therapeutic device platforms, also 40% of the set, price at 7.8x. So installed base, consumables pull-through and reimbursement exposure are what separate how the market prices these business models.

    Everything on this page

    02 · LANDSCAPE Hospital Consumables Hold the Higher Observed Segment Valuation Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Implantable and therapeutic device platforms 4 40% 7.8x LivaNova PLC (LIVN) · AdaptHealth Corp. (AHCO) · +2 more Adoption proof matters here. This group prices at 7.8x across two names with an estimate. Coverage, clinical evidence and therapy concentration remain central to the value case. Procedural instruments and single-use hospital consumables 4 40% 10.1x Solventum Corporation (SOLV) · Baxter International Inc. (BAX) · +2 more Pull-through supports durability. This group prices at 10.1x across three names with an estimate. Installed base, attach rate and consumables pull-through can soften exposure to the hospital capital budget cycle. Adjacent models 2 20% 12.2x n=1 STERIS plc (STE) · Kewaunee Scientific Corporation (KEQU) Different economics need context. One of the two names carries an estimate, so the observed valuation should be read as company-specific rather than a broad segment benchmark.

  7. 07
    SECTION 03

    03

    This divider introduces the section on public market valuation and the spread between premium and discount names.

    The valuation spread leaves room for operating progress to matter. We use this page to reset before showing how forward pricing separates the premium end of the sector from the discount end.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Valuation Spread Leaves Room for Operating Progress to Matter Forward pricing separates the premium end from the discount end. 03 of 06 Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Forward Pricing Separates Durable Platforms from Challenged Positions

    This page ranks all six rated companies by EV/EBITDA (CY2027E) against the 10.3x sector median.

    We show all six rated companies sorted by EV/EBITDA (CY2027E) against a sector median of 10.3x. The tiering separates durable platforms from more challenged positions on the same valuation basis. So where a company sits in this ranking is a useful starting point for any conversation about relative positioning.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Forward Pricing Separates Durable Platforms from Challenged Positions EV / EBITDA (CY2027E) · all 6 rated companies, sorted descending · sector median 10.3x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (6 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 13.7x CORE · median 10.3x DISCOUNT · median 6.6x Sector median 10.3x WHAT SEPARATES THE TWO ENDS The spread remains wide. The premium end prices at 13.7x, compared with 6.6x at the discount end. Forward pricing tests durability. The multiple already reflects forecast earnings, so a sustained premium signals confidence beyond near-term growth. Revenue quality still matters. Recurring consumables, service renewal and reimbursement durability give owners clearer ways to defend the earnings base.

  9. 09
    03 · VALUATION DRIVERS

    Faster-Growing Names Hold the Higher Forward Valuation

    This page splits the rated companies into growth and margin cohorts and compares their median EV/EBITDA.

    We split the rated companies with estimates into faster- and slower-growth cohorts, and separately into higher- and lower-margin cohorts, each cut at its own covered median. Faster-growing names price at 12.2x versus 8.1x for slower-growing peers, an association rather than a proven cause. So profitable growth appears to sit at the centre of how this market prices these companies.

    Everything on this page

    03 · VALUATION DRIVERS Faster-Growing Names Hold the Higher Forward Valuation Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=3; slower n=3; higher-margin n=3; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 4% · EBITDA-margin split at 23% Growth Separates the Observed Valuation Groups On the six names with an estimate, the three above the 4% split price at 12.2x, compared with 8.1x for the three below. Growth Still Needs an Earnings Base Installed-base expansion is more defensible when placements carry consumables pull-through, service revenue or reimbursement support. Durability Can Protect the Forward Case Retention, reorder behaviour and quality-system discipline help distinguish repeatable earnings from a temporary capital cycle.

  10. 10
    03 · SITUATION MAP

    Value Sits with the Higher-Margin Names That Hold Their Market Standing

    This page maps companies on EV/EBITDA versus the sector median against EBITDA margin versus the covered median.

    We cut the rated set on EV/EBITDA against the 10.3x sector median and on EBITDA margin against the 23% covered median to see where value concentrates. The read is that value sits with higher-margin names that hold their market standing. These are observations on where companies sit today, not recommendations to buy or sell any security.

    Everything on this page

    03 · SITUATION MAP Value Sits with the Higher-Margin Names That Hold Their Market Standing Cut on EV / EBITDA vs the sector median (10.3x) (rows) and EBITDA margin vs the covered median (23%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Margin Above-median multiple · above-median EBITDA margin 2 names STERIS plc (STE) · Stevanato Group S.p.A. (STVN) These names combine above-line valuation with above-line profitability. The priority is protecting recurring mix, service quality and operating discipline. Premium Before Margin Above-median multiple · below-median EBITDA margin 1 names LivaNova PLC (LIVN) The valuation is above the reference line while profitability is below it. Margin progression can test whether the premium is durable. Margin Before Premium Below-median multiple · above-median EBITDA margin 1 names Solventum Corporation (SOLV) Profitability is above the reference line while valuation is below it. The operating question is whether growth, mix or capital exposure is limiting recognition. Value Under Pressure Below-median multiple · below-median EBITDA margin 2 names Baxter International Inc. (BAX) · AdaptHealth Corp. (AHCO) Both valuation and profitability sit below the reference lines. The agenda centres on revenue quality, cost structure and portfolio focus.

  11. 11
    03 · THE AGENDA

    Growth, Margin and Revenue Mix Are Where the Valuation Gap Shows Up

    This page frames growth, margin and revenue mix as the questions an owner or acquirer should resolve.

    Growth, margin and revenue mix are where the valuation gap in this data shows up, and we frame them here as questions rather than answers. These are NeuraCap views grounded in the cohort data shown earlier, not investment advice. So the practical use of this page is to structure the diligence conversation, not to settle it.

    Everything on this page

    03 · THE AGENDA Growth, Margin and Revenue Mix Are Where the Valuation Gap Shows Up NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Deepen Recurring Revenue Increase consumables pull-through, service attach and renewal across the installed base. What changes the answer: Placement growth is not translating into repeat revenue or stronger contribution. Rework the Portfolio Prioritise products with durable reimbursement, attractive reorder behaviour and manageable quality-system demands. What changes the answer: Capital and management attention remain tied to low-return or concentrated product lines. Build or Partner Selectively Compare internal investment with partnerships or acquisitions where a new therapy or call point can use existing commercial infrastructure. What changes the answer: The installed base or field organisation can support adjacent products without disproportionate cost. Protect Earnings Quality Address payer concentration, field inventory, remediation spending and capital-cycle exposure before they weaken operating flexibility. What changes the answer: Forecast earnings depend on temporary demand, add-backs or concentrated counterparties.

  12. 12
    SECTION 04

    04

    This divider introduces the section on precedent transactions in the sector.

    Precedent transactions favour buyers with conviction. We use this page to reset before walking through how agreed terms vary with strategic fit, earnings quality and adoption risk.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Favour Buyers with Conviction Agreed terms vary widely across strategic fit, earnings quality and adoption risk. 04 of 06 Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Agreed Terms Widen When Strategic Fit or Earnings Quality Stands Out

    This page profiles three of nine transactions with disclosed terms as case studies, with the complete list in the appendix.

    We walk through three of nine transactions with disclosed terms, using LTM multiples at announcement where they were disclosed. The Hologic transaction, valued at $17.9B and 13.6x EV/EBITDA, is one example where agreed terms widened around strategic fit. These deal multiples sit on a different basis from the CY2027E public comparables, so we are not claiming a spread between them, but the pattern is instructive. So strategic fit and earnings quality are worth surfacing early in any transaction conversation.

    Everything on this page

    04 · DEAL CASE STUDIES Agreed Terms Widen When Strategic Fit or Earnings Quality Stands Out 3 of 9 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 23 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 14 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Oct-2025 $17.9B affiliates of Blackstone Inc. and TPG Capital Hologic, Inc. drew sponsor backing at substantial scale. EV / LTM revenue 4.3x EV / LTM EBITDA 13.6x WHY THE DEAL HAPPENED The transaction suggests affiliates of Blackstone Inc. and TPG Capital saw a platform suited to long-term sponsor ownership. Its size points to conviction in the breadth and durability of the earnings base. HOW THE TARGET WAS VALUED The announced transaction records $17.9B of value, 4.3x EV / Revenue and 13.6x EV / EBITDA. The earnings benchmark sits above the public peer set's middle. May-2019 $6.7B 3M Company Acelity LP, Inc. offered a sizeable strategic addition. EV / LTM revenue n/a EV / LTM EBITDA 15.2x WHY THE DEAL HAPPENED The transaction suggests the target offered a meaningful extension to a diversified equipment portfolio. The strategic fit points to value in adding established products and commercial reach. HOW THE TARGET WAS VALUED The announced transaction records $6.7B of value and 15.2x EV / EBITDA. That multiple sits toward the upper end of the observed transaction record. May-2024 $802M Nordson Corporation Atrion Corporation secured premium strategic terms. EV / LTM revenue 4.5x EV / LTM EBITDA 19.6x WHY THE DEAL HAPPENED The combination with Nordson Corporation suggests a strategic adjacency with relevance beyond standalone earnings. The agreed terms indicate conviction in the fit. HOW THE TARGET WAS VALUED The completed transaction records $802M of value, 4.5x EV / Revenue and 19.6x EV / EBITDA. Both measures provide a premium transaction benchmark.

  14. 14
    SECTION 05

    05

    This divider introduces the section on strategic implications for owners, management and boards.

    Strengthen the revenue engine before choosing the capital path. We use this page to reset before setting out what this data means for owners, management teams and boards over the next twelve months.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Strengthen the Revenue Engine Before Choosing the Capital Path The right priorities depend on recurring mix, profitability and strategic fit. 05 of 06 Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Revenue Quality and Operating Proof Come Before Capital Structure

    This page sets out the priority questions for owners, management teams and boards drawn from the valuation and transaction evidence.

    We put three questions on the table: which value engine to choose, how to turn placements into recurring revenue, and how to match capital to evidence of retention and margin durability. These are NeuraCap views drawn from the analysis in this report, offered as observations rather than recommendations. So the practical next step is to test where your own business sits against these questions.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Revenue Quality and Operating Proof Come Before Capital Structure NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Choose the Value Engine Decide whether the business compounds through recurring consumables, reimbursement-anchored services or therapy adoption, then align investment to that model. FOR MANAGEMENT TEAMS Turn Placements into Annuities Focus commercial effort on attach rate, reorder behaviour, service renewal and contribution per procedure rather than unit volume alone. FOR BOARDS Match Capital to Evidence Use retention, margin durability and strategic fit to frame build-versus-buy choices and portfolio allocation.

  16. 16
    SECTION 06

    06

    This divider introduces the appendix covering the full comparables universe, methodology and sources.

    The full universe, methodology and sources close out this report. We use this page to reset before the comparables detail behind every figure in the body.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This page lists the approved universe grouped by valuation tier, with six companies rated and four not rated.

    We show all six rated companies against the 10.3x sector median, with teal marking above-median pricing and amber marking below. The four companies without an eligible EV/EBITDA are listed separately in the companion workbook. So this page is the reference point for tracing any multiple used earlier in the report back to its source.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (10.3x); amber marks below · 6 rated companies; 4 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 6 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥11.8x · median 13.7x · 2 companies Stevanato Group S.p.A. STVN Procedural instruments and single-use hospital… $6.9B 15.1x 5% 29% 38 STERIS plc STE Specialty therapy device franchises $22.3B 12.2x 7% 27% 34 CORE — 8.6x–11.8x · median 10.3x · 2 companies LivaNova PLC LIVN Implantable and therapeutic device platforms $4.0B 10.6x 10% 23% 31 Solventum Corporation SOLV Procedural instruments and single-use hospital… $20.3B 10.1x -1% 24% 27 DISCOUNT — <8.6x · median 6.6x · 2 companies Baxter International Inc. BAX Procedural instruments and single-use hospital… $19.8B 8.1x 3% 21% 23 AdaptHealth Corp. AHCO Implantable and therapeutic device platforms $2.7B 5.0x -11% 18% 22

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 1)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page lists the nine transactions with disclosed terms in the tier, newest first, out of the twenty-three recorded.

    We list all nine transactions with disclosed terms, newest first, out of twenty-three recorded in this tier, with LTM multiples at announcement where disclosed. Fourteen recorded transactions without a disclosed value or multiple are kept in the companion workbook rather than shown here. So this page is where any deal referenced earlier can be traced back to its filing.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 1) All Precedent Transactions with Disclosed Terms, Newest First 9 transactions with disclosed terms in this tier (23 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 23 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 14 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2026 Utah Medical Products, Inc. → Orion Medical Supplies Ltd n/a n/a 11.9x The announced acquisition of Orion Medical Supplies Ltd by Utah Medical Products, Inc. carries 11.9x EV / EBITDA. Oct-2025 affiliates of Blackstone Inc. and TPG Capital → Hologic, Inc. $17.9B 4.3x 13.6x The announced Hologic, Inc. transaction suggests sponsor conviction in a sizeable health care equipment and supplies business. Aug-2025 Permira Holdings LLP → Channel-Markers Medical, LLC n/a 5.7x n/a Permira Holdings LLP agreed to acquire Channel-Markers Medical, LLC at 5.7x EV / Revenue. Aug-2024 The Carlyle Group → Baxter International Inc. (Vantive Kidney Care segment) n/a 0.7x 8.8x The announced acquisition of Baxter International Inc. (Vantive Kidney Care segment) carries 0.7x EV / Revenue and 8.8x EV / EBITDA. May-2024 Nordson Corporation → Atrion Corporation $802M 4.5x 19.6x The completed Atrion Corporation transaction shows the valuation available for a strategic adjacency. Jan-2021 STERIS plc → Cantel Medical Corp n/a 4.3x 22.2x The announced Cantel Medical Corp transaction carries 4.3x EV / Revenue and 22.2x EV / EBITDA. Nov-2019 MacDonald, Dettwiler and Associates Ltd. → Endoclear LLC n/a 4.7x 7.3x The announced Endoclear LLC transaction carries 4.7x EV / Revenue and 7.3x EV / EBITDA. May-2019 3M Company → Acelity LP, Inc. $6.7B n/a 15.2x The announced Acelity LP, Inc. transaction paired a sizeable platform with a diversified strategic portfolio. Oct-2014 Steris Corporation → Synergy Health plc n/a n/a 13.0x The announced Synergy Health plc transaction carries 13.0x EV / EBITDA.

  19. 19
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Sources, Assumptions and Data Quality.

    Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 19

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice 19 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (6 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Health Care Equipment and Supplies and it clears the coverage gate with 6 of 10 companies (60%). EV / Revenue, P / E are carried as a cross-check. The set earns: 6 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 17 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 458 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (457) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  20. 20

    In This Sample, Premium Positions Align with Growth, Margin and Durable Revenue.

    This is the closing page restating that premium positions align with growth, margin and durable revenue in this sample.

    In this sample, premium positions align with growth, margin and durable revenue. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure you want to trace further. So the evidence points toward profitable, recurring revenue as the throughline for value in this sector.

    Everything on this page

    In This Sample, Premium Positions Align with Growth, Margin and Durable Revenue. NeuraCap AI — Health Care Equipment and Supplies Coverage September 2026 · Prepared by NeuraCap AI · Confidential Health Care Equipment and Supplies Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20

Sources and methodology

This report covers Health Care Equipment and Supplies (Health Care › Health Care Equipment and Services › Health Care Equipment and Supplies) with market data and consensus estimates as of September 28, 2026. The company universe is the 10 listed companies whose core business is Health Care Equipment and Supplies according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AdaptHealth Corp. (AHCO), Baxter International Inc. (BAX), Cerus Corporation (CERS), IRadimed Corporation (IRMD), Kewaunee Scientific Corporation (KEQU), LivaNova PLC (LIVN), Nyxoah S.A. (NYXH), Solventum Corporation (SOLV), STERIS plc (STE), Stevanato Group S.p.A. (STVN). The market map groups them by business vertical — Implantable and therapeutic device platforms: 4 companies (LIVN, AHCO, IRMD, CERS); Procedural instruments and single-use hospital consumables: 4 companies (SOLV, BAX, STVN, NYXH); Adjacent models: 2 companies (STE, KEQU). 6 of the 10 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Health Care Equipment and Supplies (Health Care › Health Care Equipment and Services › Health Care Equipment and Supplies) with market data and consensus estimates as of September 28, 2026. The company universe is the 10 listed companies whose core business is Health Care Equipment and Supplies according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AdaptHealth Corp. (AHCO), Baxter International Inc. (BAX), Cerus Corporation (CERS), IRadimed Corporation (IRMD), Kewaunee Scientific Corporation (KEQU), LivaNova PLC (LIVN), Nyxoah S.A. (NYXH), Solventum Corporation (SOLV), STERIS plc (STE), Stevanato Group S.p.A. (STVN). The market map groups them by business vertical — Implantable and therapeutic device platforms: 4 companies (LIVN, AHCO, IRMD, CERS); Procedural instruments and single-use hospital consumables: 4 companies (SOLV, BAX, STVN, NYXH); Adjacent models: 2 companies (STE, KEQU). 6 of the 10 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

17 records failed a validation gate and never feed a statistic in this report (16 excluded from aggregate; 1 quarantined). Each exclusion, with its reason: AHCO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AHCO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AHCO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BAX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CERS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LIVN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NYXH — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · NYXH — Implied EBITDA margin -827.4% outside the plausible band [-100%, 80%] (effect: quarantined) · NYXH — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · NYXH — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · NYXH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NYXH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NYXH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NYXH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (6 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Health Care Equipment and Supplies and it clears the coverage gate with 6 of 10 companies (60%). EV / Revenue, P / E are carried as a cross-check. The set earns: 6 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 6 of 10 companies; EV / rEVenue: 9 of 10 companies; P/E: 6 of 10 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 3 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥11.8x, Core 8.6x–11.8x, Discount <8.6x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 10.3x = median(ev_ebitda CY2027E) (6 rated companies) · 13.7x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 10.3x = median(ev_ebitda CY2027E) within Core tier (n=2) · 6.6x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 12.2x = median(ev_ebitda CY2027E) | growth ≥ 4% (n=3) · 8.1x = median(ev_ebitda CY2027E) | growth < 4% (n=3) · 12.2x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 23% (n=3) · 8.1x = median(ev_ebitda CY2027E) | EBITDA margin < 23% (n=3) · 29% = median Rule of 40 score (revenue growth + EBITDA margin) (n=6)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Health Care Equipment and Supplies recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 23 transactions were recorded for this industry; 9 are shown. 14 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 9 × deal value unit unresolved; 11 × no evidence record; 1 × duplicate precedent id; 2 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 462 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Health Care Equipment and Supplies?

Company valuation reports run the same method against a single business — public or private.